# China NMPA Drug Inspection - Hunan Honghua Traditional Chinese Medicine Pieces Co., Ltd. - Sophora tonkinensis

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hunan-honghua-traditional-chinese-medicine-pieces-co-ltd/8b395d5d-0114-474f-8352-59e74107d493/
Source feed: China

> China NMPA drug inspection for Hunan Honghua Traditional Chinese Medicine Pieces Co., Ltd. published December 22, 2020. Drug: Sophora tonkinensis. The Guizhou Provincial Drug Administration recently published its third drug quality announcement for 2020, identifying 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Guizhou Provincial Drug Administration Drug Quality Bulletin (Drug Sampling Inspection Information Announcement) (Issue 3, 2020) (Total Issue 41)
- Company Name: Hunan Honghua Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2020-12-22
- Drug Name: Sophora tonkinensis
- Inspection Finding: The product does not meet the requirements; the non-compliant item is [appearance/property].
- Action Taken: Drug regulatory authorities at all levels are required to investigate and prosecute any substandard drugs found in random inspections within their jurisdictions in accordance with relevant laws and regulations, and to strengthen supervision of relevant entities, urging them to correct illegal activities and enhance risk prevention and control.
- Summary: The Guizhou Provincial Drug Administration recently published its third drug quality announcement for 2020, identifying ten batches of substandard drugs from eight pharmaceutical manufacturers. This initiative, conducted under the 'Drug Administration Law of the People's Republic of China' and the 'Administrative Measures for Drug Quality Sampling Inspection,' aimed to ensure public safety through rigorous sampling of producers and distributors. The inspection identified several prominent manufacturers, including Guizhou Jingfeng Injection Co., Ltd., Jilin Aodong Taonan Pharmaceutical Co., Ltd., and Anhui Zehua Traditional Chinese Medicine Pieces Co., Ltd. Key violations involved failures to meet the standards of the Chinese Pharmacopoeia (2015). Specific issues included improper moisture levels, rancidity, and insufficient active ingredient content, such as glycyrrhizin and osthol. Furthermore, physical appearance discrepancies were noted, and some instances involved disputed authenticity or denied production by the labeled manufacturers. In response, the Guizhou Provincial Drug Administration has ordered regulatory departments at all levels to initiate investigations and prosecutions. The sampled units must correct illegal activities and enhance their risk management protocols to prevent future non-compliance. This measure emphasizes the provincial commitment to maintaining high pharmaceutical standards and protecting consumers from ineffective or potentially harmful medications.

Company: https://www.globalkeysolutions.net/companies/hunan-honghua-traditional-chinese-medicine-pieces-co-ltd/58047b25-16d8-420f-92ca-50b0361494ef/